Chinese bio technology Company Ionova Raised ￥126 Million in a Series A Round Funding Led by Lilly Asia Ventures and followed by Dyee Capital. The investment will be used to advance projects into clinical research, and accelerate R&D.
Established in 2016, Ionova is committed to the R&D of innovative targeted agents for tumors and immune regulation drugs for tumor.
South Africa Today
Read more at VolaNews
